Gilead Sciences’ annual HIV prevention injection shows promise in clinical trial, Lancet study reveals

​ 

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 weeks, according to the phase 1 randomised controlled trial.

 The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 weeks, according to the phase 1 randomised controlled trial.